Top Genentech researcher steps away and Roche turns to the Broad for a star replacement player
Michael Varney is stepping away from his top post in Genentech R&D, and the storied biotech is plucking a star cell expert from the Broad as his replacement.
Aviv Regev will now be taking a leading role in a $10 billion research organization as head of Genentech Research and Early Development, better known as gRED to Basel-based pRED, and joining the executive committee at Roche. After picking up her PhD at Tel Aviv University in computational biology, Regev went on to become a top investigator in biological networks, gene regulation and evolution.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.